Mauna Kea Technologies Overhauls International Commercial Team to Expand CellTolerance and Pancreatic Cyst Markets
Event summary
- Mauna Kea Technologies appoints Benoit Chardon as Fractional Chief Commercial Officer to lead CellTolerance® expansion outside the U.S.
- CellTolerance® reached €1 million in sales in 2025, positioning it as a second growth pillar alongside pancreatic cyst characterization.
- New commercial organization targets Europe, the Middle East, and Australia for accelerated growth in 2026.
- Pancreatic cyst characterization leverages positive CLIMB study results and ESGE guideline inclusion.
The big picture
Mauna Kea Technologies is sharpening its focus on international markets following a successful U.S. commercial restructuring in 2025. The company aims to capitalize on the clinical momentum of pancreatic cyst characterization and the rapid scaling of CellTolerance®, which has shown strong market traction globally. The strategic reorganization underscores a shift towards disciplined, high-quality scaling to address large, underserved markets in food intolerance diagnosis and pancreatic cyst management.
What we're watching
- Execution Risk
- Whether Benoit Chardon can replicate his scalable playbooks for CellTolerance® in new international markets.
- Regulatory Dynamics
- The pace at which the French National Authority for Health review could unlock reimbursement for Cellvizio® in pancreatic cysts.
- Market Penetration
- How strategic partnerships with leading clinics and distributors will impact CellTolerance®'s growth trajectory.
Related topics